Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BALCHEM CORPBCPC · Entity 3839 | Chief Financial Officer | October 26, 2018 | October 30, 2018 |
| BIODELIVERY SCIENCES INTERNATIONAL INCBDSI · Entity 128876 | See Remarks | January 29, 2021 | February 02, 2021 |
| CinCor Pharma, Inc.CINC · Entity 116342 | EVP CFO & Chief BD Officer | January 11, 2022 | January 13, 2022 |
| Gamida Cell Ltd.GMDA · Entity 94655 | Chief Financial Officer | June 12, 2023 | June 14, 2023 |
| GridAI Technologies Corp.FWBI · Entity 7534 | Director | January 02, 2024 | January 04, 2024 |
| HOOKIPA Pharma Inc.HOOK · Entity 15295 | Director · EVP and CFO | July 22, 2025 | July 23, 2025 |
| Inotiv, Inc.NOTVQ · Entity 29609 | Director | July 19, 2026 | July 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BALCHEM CORP
Report date October 26, 2018 · Filed October 30, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,105 |
Reported balance
After 2018-10-29 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-10-29 · Tax withholding · Disposed 1,187 · Balance 2,105 F1: The Company granted 5,605 restricted shares under the Company's Long-Term Incentive Program. The shares were subject to certain restrictions under the applicable Restricted Stock Grant Agreements. 1,187 of the 3,210 shares that vested October 26, 2018 were withheld to cover withholding taxes due upon vesting. F2: In connection with a Separation Agreement and General Release (SA&GR) between the Company and the reporting person, 1,050 shares previously reported as beneficially owned in connection with Restricted Stock Grant Agreements were forfeited. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $74.57 · Expires 2028-02-15 | Direct | 3,337 |
Reported balance
After 2018-10-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-10-26 · Grant · Acquired 1,132 · Balance 3,337 F3: On February 15, 2018, the reporting person was granted an option to purchase 5,030 shares of common stock scheduled to vest in installments of 20%, 40%, and 40% per year over the three-year period. The option reported herein as acquired resulted from the acceleration of vesting of 22.5% of such option in connection with a SA&GR. |
Filing footnotes · ownership attribution and instrument terms
F1: The Company granted 5,605 restricted shares under the Company's Long-Term Incentive Program. The shares were subject to certain restrictions under the applicable Restricted Stock Grant Agreements. 1,187 of the 3,210 shares that vested October 26, 2018 were withheld to cover withholding taxes due upon vesting.
F2: In connection with a Separation Agreement and General Release (SA&GR) between the Company and the reporting person, 1,050 shares previously reported as beneficially owned in connection with Restricted Stock Grant Agreements were forfeited.
F3: On February 15, 2018, the reporting person was granted an option to purchase 5,030 shares of common stock scheduled to vest in installments of 20%, 40%, and 40% per year over the three-year period. The option reported herein as acquired resulted from the acceleration of vesting of 22.5% of such option in connection with a SA&GR.
BIODELIVERY SCIENCES INTERNATIONAL INC
Report date January 29, 2021 · Filed February 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,079 |
Reported balance
After 2021-01-29 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-01-29 · Exercise / conversion · Acquired 10,190 · Balance 34,079 |
| Common StockSEC Table I · non-derivative | Direct | 30,619 |
Reported balance
After 2021-02-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2021-02-01 · Sale · Disposed 3,460 · Balance 30,619 F1: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2: On February 1, 2021, the Reporting Person sold an aggregate of 3,460 shares of the Issuer's Common Stock at a weighted average price of $3.87 per share. The highest sale price for the Common Stock was $3.89 per share and the lowest sale price was $3.87 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2023-01-29 | Direct | 20,381 |
Reported balance
After 2021-01-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-01-29 · Exercise / conversion · Disposed 10,190 · Balance 20,381 F3: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 10,190 Restricted Stock Units ("RSUs") granted to the Reporting Person on January 29, 2020 under the Issuer's 2019 Stock Option Incentive Plan, as amended. The remainder of the RSUs under this grant will vest in equal portions on January 29, 2022 and January 29, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan.
F2: On February 1, 2021, the Reporting Person sold an aggregate of 3,460 shares of the Issuer's Common Stock at a weighted average price of $3.87 per share. The highest sale price for the Common Stock was $3.89 per share and the lowest sale price was $3.87 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.
F3: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 10,190 Restricted Stock Units ("RSUs") granted to the Reporting Person on January 29, 2020 under the Issuer's 2019 Stock Option Incentive Plan, as amended. The remainder of the RSUs under this grant will vest in equal portions on January 29, 2022 and January 29, 2023.
CinCor Pharma, Inc.
Report date January 11, 2022 · Filed January 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy child | 100 |
Reported balance
After 2022-01-11 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2022-01-11 · Purchase · Acquired 100 · Balance 100 F1: The securities are held by the Reporting Person's child. The Reporting Person shares voting and investment control of the shares and may be deemed to beneficially own the shares. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities are held by the Reporting Person's child. The Reporting Person shares voting and investment control of the shares and may be deemed to beneficially own the shares. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her proportionate pecuniary interest therein.
Gamida Cell Ltd.
Report date June 12, 2023 · Filed June 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.98 · Expires 2033-06-11 | Direct | 10,000 |
Reported balance
After 2023-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-12 · Grant · Acquired 10,000 · Balance 10,000 F1: This option vests on the earlier of (i) the date of the closing of a Merger/Sale (as such term is defined under the Issuer's 2017 Share Incentive Plan (as amended)), or (ii) May 22, 2024, so long as, prior to such date, (x) the Reporting Person has not terminated without cause the Reporting Person's Consulting Agreement (the "Agreement") with the Issuer or (y) the Issuer has not terminated the Agreement for breach (and such breach has not been cured). |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests on the earlier of (i) the date of the closing of a Merger/Sale (as such term is defined under the Issuer's 2017 Share Incentive Plan (as amended)), or (ii) May 22, 2024, so long as, prior to such date, (x) the Reporting Person has not terminated without cause the Reporting Person's Consulting Agreement (the "Agreement") with the Issuer or (y) the Issuer has not terminated the Agreement for breach (and such breach has not been cured).
GridAI Technologies Corp.
Report date January 02, 2024 · Filed January 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,237 |
Reported balance
After 2024-01-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-01-02 · Grant · Acquired 19,633 · Balance 20,237 F1: On January 2, 2024, the Reporting Person was granted 19,633 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning April 1, 2024. F2: Includes unvested RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 2, 2024, the Reporting Person was granted 19,633 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning April 1, 2024.
F2: Includes unvested RSUs.
HOOKIPA Pharma Inc.
Report date July 22, 2025 · Filed July 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 56,266 |
Reported balance
After 2025-07-22 transaction · row 1
1 source rowRow 1 · 2025-07-22 · Sale · Disposed 13,609 · Balance 56,266 F1: This sale was affected pursuant to a "sell to cover" arrangement adopted by the Issuer to satisfy the tax withholding obligations triggered by the vesting of restricted stock units granted on July 22, 2024 and does not represent a discretionary trade by the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was affected pursuant to a "sell to cover" arrangement adopted by the Issuer to satisfy the tax withholding obligations triggered by the vesting of restricted stock units granted on July 22, 2024 and does not represent a discretionary trade by the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
Inotiv, Inc.
Report date July 19, 2026 · Filed July 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-07-19 transaction · row 1
1 source rowRow 1 · 2026-07-19 · Other · Disposed 74,303 · Balance 0 F1: The Amended Joint Prepackaged Chapter 11 Plan of Reorganization of Inotiv, Inc. and its Affiliated Debtors (the "Plan") under Chapter 11 of the Bankruptcy Code was confirmed by the United States Bankruptcy Court for the Southern District of Texas, Houston Division, on July 14, 2026, and became effective on July 19, 2026. On the effective date of the Plan, all outstanding common shares and other equity interests of Inotiv, Inc. were canceled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: The Amended Joint Prepackaged Chapter 11 Plan of Reorganization of Inotiv, Inc. and its Affiliated Debtors (the "Plan") under Chapter 11 of the Bankruptcy Code was confirmed by the United States Bankruptcy Court for the Southern District of Texas, Houston Division, on July 14, 2026, and became effective on July 19, 2026. On the effective date of the Plan, all outstanding common shares and other equity interests of Inotiv, Inc. were canceled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 19, 2026 Filed Jul 20, 2026 20:27 UTC | Inotiv, Inc. NOTVQ · Entity 29609 | OtherCommon Stock | 74,303 | $0.00 | $0.00 |
DisclosureSEC source: 0001720772-26-000002 · form4-07202026_080756.xml · nonDerivative · entry 1 Coelho Mary Theresa · CIK 0001720772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The Amended Joint Prepackaged Chapter 11 Plan of Reorganization of Inotiv, Inc. and its Affiliated Debtors (the "Plan") under Chapter 11 of the Bankruptcy Code was confirmed by the United States Bankruptcy Court for the Southern District of Texas, Houston Division, on July 14, 2026, and became effective on July 19, 2026. On the effective date of the Plan, all outstanding common shares and other equity interests of Inotiv, Inc. were canceled for no consideration. Read SEC document |
| July 22, 2025 Filed Jul 23, 2025 22:07 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | SaleCommon Stock | 13,609 | $0.92 | $12,520.28 |
DisclosureSEC source: 0001415889-25-020198 · form4-07232025_100733.xml · nonDerivative · entry 1 Coelho Mary Theresa · CIK 0001720772 · Director · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,266 F1 · kind: This sale was affected pursuant to a "sell to cover" arrangement adopted by the Issuer to satisfy the tax withholding obligations triggered by the vesting of restricted stock units granted on July 22, 2024 and does not represent a discretionary trade by the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 20:32 UTC | Inotiv, Inc. NOTV · Entity 29609 | SaleCommon Stock | 5,500 | $2.35 | $12,915.65 |
DisclosureSEC source: 0001062993-25-006842 · form4.xml · nonDerivative · entry 1 Coelho Mary Theresa · CIK 0001720772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,303 F1 · shares: These shares were sold to cover taxes associated with the restricted stock units that vested on March 31, 2025. F2 · price: Reflects the weighted average price of 5,500 shares of common stock of Inotiv, Inc. sold by the reporting person in multiple transactions on April 1, 2025 with sales prices ranging from $2.175 to $2.42 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:09 UTC | Inotiv, Inc. NOTV · Entity 29609 | GrantCommon Stock | 39,392 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-005700 · form4.xml · nonDerivative · entry 1 Coelho Mary Theresa · CIK 0001720772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,803 F1 · shares: Represents a grant of restricted stock units which vest in full on March 14, 2026, or immediately prior to the next annual meeting of stockholders if stepping down from the Board. Read SEC document |
| August 10, 2024 Filed Aug 15, 2024 01:34 UTC | Inotiv, Inc. NOTV · Entity 29609 | GrantCommon Stock | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-015126 · form4.xml · nonDerivative · entry 1 Coelho Mary Theresa · CIK 0001720772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,411 F1 · shares: Represents a grant of restricted stock units which vest in full on March 31, 2025, provided that the grantee continues to serve as a director of the Company through the vesting date. Read SEC document |
| July 22, 2024 Filed Jul 24, 2024 20:18 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | GrantCommon Stock | 69,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-020043 · form4-07242024_080711.xml · nonDerivative · entry 1 Coelho Mary Theresa · CIK 0001720772 · Director · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,875 F1 · shares: Grant to the Reporting Person of a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of common stock of the Issuer. F2 · shares: The RSU shall vest in two equal installments on July 22, 2025 and July 22, 2026, subject to the Reporting Person's continuous service through each such date. Read SEC document |
| June 17, 2024 Filed Jun 18, 2024 20:15 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | GrantStock Option (Right to Buy) · Derivative | 49,000 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001415889-24-017388 · form4-06182024_040611.xml · derivative · entry 1 Coelho Mary Theresa · CIK 0001720772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,000 Underlying: Common Stock · 49,000 shares Expires 2034-06-17 F1 · derivative.exercise_date: This option award shall vest and become fully exercisable on the earlier to occur of (a) June 17, 2025 and (b) the date of the Issuer's next annual meeting of its stockholders. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 22:13 UTC | GridAI Technologies Corp. FWBI · Entity 7534 | GrantCommon Stock | 19,633 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-001438 · tm242126-1_4seq1.xml · nonDerivative · entry 1 Coelho Mary Theresa · CIK 0001720772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,237 F1 · shares: On January 2, 2024, the Reporting Person was granted 19,633 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning April 1, 2024. F2 · balance_after: Includes unvested RSUs. Read SEC document |
| October 17, 2023 Filed Oct 18, 2023 20:16 UTC | Inotiv, Inc. NOTV · Entity 29609 | GrantCommon Stock | 12,911 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-019536 · form4.xml · nonDerivative · entry 1 Coelho Mary Theresa · CIK 0001720772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,911 F1 · shares: Represents a grant of restricted stock units, which vests on April 1, 2024, provided that the grantee continues to serve as a director of the Company through such date. Read SEC document |
| June 12, 2023 Filed Jun 14, 2023 16:21 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantShare Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001209191-23-037015 · doc4.xml · derivative · entry 1 Coelho Mary Theresa · CIK 0001720772 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2033-06-11 F1 · derivative.exercise_date: This option vests on the earlier of (i) the date of the closing of a Merger/Sale (as such term is defined under the Issuer's 2017 Share Incentive Plan (as amended)), or (ii) May 22, 2024, so long as, prior to such date, (x) the Reporting Person has not terminated without cause the Reporting Person's Consulting Agreement (the "Agreement") with the Issuer or (y) the Issuer has not terminated the Agreement for breach (and such breach has not been cured). Read SEC document |
| June 09, 2023 Filed Jun 9, 2023 21:13 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | GrantStock Option (Right to Buy) · Derivative | 52,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001104659-23-069996 · tm2318326-1_4seq1.xml · derivative · entry 1 Coelho Mary Theresa · CIK 0001720772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 52,000 shares Expires 2033-06-09 F1 · derivative.exercise_date: One-third of this option shall vest on June 9, 2024, with the remainder vesting in 8 equal quarterly installments thereafter. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 14:02 UTC | GridAI Technologies Corp. FWBI · Entity 7534 | GrantCommon Stock | 84,745 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-001231 · tm231522-7_4seq1.xml · nonDerivative · entry 1 Coelho Mary Theresa · CIK 0001720772 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,745 F1 · shares: On January 3, 2023, the Reporting Person was granted 84,745 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning March 31, 2023. F2 · balance_after: Includes unvested RSUs. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 21:24 UTC | CinCor Pharma, Inc. CINC · Entity 116342 | PurchaseCommon Stock | 100 | $16.00 | $1,600.00 |
DisclosureSEC source: 0001209191-22-003184 · doc4.xml · nonDerivative · entry 1 Coelho Mary Theresa · CIK 0001720772 · EVP CFO & Chief BD Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By child Disclosed balance after: 100 F1 · ownership.nature: The securities are held by the Reporting Person's child. The Reporting Person shares voting and investment control of the shares and may be deemed to beneficially own the shares. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her proportionate pecuniary interest therein. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 02:07 UTC | GridAI Technologies Corp. FWBI · Entity 7534 | GrantStock option (right to buy) · Derivative | 34,482 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001140361-22-000303 · form4.xml · derivative · entry 1 Coelho Mary Theresa · CIK 0001720772 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,482 Underlying: Common stock, par value $0.0001 per share · 34,482 shares Expires 2032-01-03 F1 · derivative.exercise_date: The stock option vests in equal quarterly installments on each of March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Read SEC document |
| September 09, 2021 Filed Sep 14, 2021 00:08 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GrantStock option (right to buy) · Derivative | 10,310 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001415889-21-004371 · form4-09132021_050904.xml · derivative · entry 1 Coelho Mary Theresa · CIK 0001720772 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,310 Underlying: Common stock, par value $0.0001 per share · 10,310 shares Expires 2031-09-09 F1 · shares: The number of derivative securities reported has not been adjusted to reflect the 10-for-1 reverse stock split of AzurRx BioPharma, Inc. common stock that occurred on September 13, 2021. F2 · derivative.exercise_date: The stock option vests on December 31, 2021. F1 · derivative.underlying_shares: The number of derivative securities reported has not been adjusted to reflect the 10-for-1 reverse stock split of AzurRx BioPharma, Inc. common stock that occurred on September 13, 2021. F1 · balance_after: The number of derivative securities reported has not been adjusted to reflect the 10-for-1 reverse stock split of AzurRx BioPharma, Inc. common stock that occurred on September 13, 2021. Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 19:12 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 3,460 | $3.87 | $13,390.20 |
DisclosureSEC source: 0001103021-21-000018 · wf-form4_161231111864978.xml · nonDerivative · entry 2 Coelho Mary Theresa · CIK 0001720772 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,619 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2 · price: On February 1, 2021, the Reporting Person sold an aggregate of 3,460 shares of the Issuer's Common Stock at a weighted average price of $3.87 per share. The highest sale price for the Common Stock was $3.89 per share and the lowest sale price was $3.87 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 19:12 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 10,190 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001103021-21-000018 · wf-form4_161231111864978.xml · derivative · entry 3 Coelho Mary Theresa · CIK 0001720772 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,381 Underlying: Common Stock · 10,190 shares Expires 2023-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 10,190 Restricted Stock Units ("RSUs") granted to the Reporting Person on January 29, 2020 under the Issuer's 2019 Stock Option Incentive Plan, as amended. The remainder of the RSUs under this grant will vest in equal portions on January 29, 2022 and January 29, 2023. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 19:12 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 10,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001103021-21-000018 · wf-form4_161231111864978.xml · nonDerivative · entry 1 Coelho Mary Theresa · CIK 0001720772 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 19:06 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantRestricted Stock Units · Derivative | 62,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001103021-21-000008 · wf-form4_161196520326361.xml · derivative · entry 2 Coelho Mary Theresa · CIK 0001720772 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2024-01-27 F3 · kind: The Restricted Stock Units ("RSUs") were issued to the Reporting Person on January 27, 2021, pursuant to a grant under the Plan. The award is subject to time-based vesting and will vest in equal portions on: (i) January 27, 2022; (ii) January 27, 2023; and (iii) January 27, 2024. F4 · derivative.exercise_date: Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 19:06 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantStock Options (right to buy) · Derivative | 344,632 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001103021-21-000008 · wf-form4_161196520326361.xml · derivative · entry 1 Coelho Mary Theresa · CIK 0001720772 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,632 Underlying: Common Stock · 344,632 shares Expires 2031-01-26 F1 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on January 27, 2021. F2 · kind: The stock options were issued to the Reporting Person on January 27, 2021, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan (the "Plan"). The award is subject to time-based vesting and will vest in equal portions on: (i) January 27, 2022; (ii) January 27, 2023; and (iii) January 27, 2024. F2 · derivative.exercise_date: The stock options were issued to the Reporting Person on January 27, 2021, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan (the "Plan"). The award is subject to time-based vesting and will vest in equal portions on: (i) January 27, 2022; (ii) January 27, 2023; and (iii) January 27, 2024. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 16:30 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 6,462 | $4.32 | $27,915.84 |
DisclosureSEC source: 0001103021-21-000002 · wf-form4_161117821292460.xml · nonDerivative · entry 2 Coelho Mary Theresa · CIK 0001720772 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,889 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2 · price: On January 19, 2021, the Reporting Person sold an aggregate of 6,462 shares of the Issuer's Common Stock at a weighted average price of $4.32 per share. The highest sale price for the Common Stock was $4.34 per share and the lowest sale price was $4.32 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 16:30 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 18,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001103021-21-000002 · wf-form4_161117821292460.xml · derivative · entry 3 Coelho Mary Theresa · CIK 0001720772 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,334 Underlying: Common Stock · 18,333 shares Expires 2022-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 18,333 Restricted Stock Units ("RSUs") granted to the Reporting Person on January 17, 2019 under the Issuer's 2011 Equity Incentive Plan, as amended. The remainder of the RSUs under this grant vest on January 15, 2022. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 16:30 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 18,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001103021-21-000002 · wf-form4_161117821292460.xml · nonDerivative · entry 1 Coelho Mary Theresa · CIK 0001720772 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 17:46 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantRestricted Stock Units · Derivative | 30,571 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001103021-20-000019 · wf-form4_158051076576609.xml · derivative · entry 2 Coelho Mary Theresa · CIK 0001720772 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,571 Underlying: Common Stock · 30,571 shares Expires 2023-01-29 F3 · kind: The Restricted Stock Units ("RSUs") were issued to the Reporting Person on January 29, 2020, pursuant to a grant under the Plan. The award is subject to time-based vesting and will vest in equal portions on: (i) January 29, 2021; (ii) January 29, 2022; and (iii) January 29, 2023. F4 · derivative.exercise_date: Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 17:46 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantStock Options (right to buy) · Derivative | 148,665 | $0.00 Strike: $6.17 | $0.00 |
DisclosureSEC source: 0001103021-20-000019 · wf-form4_158051076576609.xml · derivative · entry 1 Coelho Mary Theresa · CIK 0001720772 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,665 Underlying: Common Stock · 148,665 shares Expires 2030-01-29 F1 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is the volume-weighted average price of the Issuer's common stock for the 30-day period ending on January 28, 2020. F2 · kind: The stock options were issued to the Reporting Person on January 29, 2020, pursuant to a grant under the Issuer's 2019 Stock Option and Incentive Plan (the "Plan"). The award is subject to time-based vesting and will vest in equal portions on: (i) January 29, 2021; (ii) January 29, 2022; and (iii) January 29, 2023. F2 · derivative.exercise_date: The stock options were issued to the Reporting Person on January 29, 2020, pursuant to a grant under the Issuer's 2019 Stock Option and Incentive Plan (the "Plan"). The award is subject to time-based vesting and will vest in equal portions on: (i) January 29, 2021; (ii) January 29, 2022; and (iii) January 29, 2023. Read SEC document |
| January 16, 2020 Filed Jan 17, 2020 16:06 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 42,018 | $5.98 | $251,267.64 |
DisclosureSEC source: 0001103021-20-000010 · wf-form4_157929516784215.xml · nonDerivative · entry 3 Coelho Mary Theresa · CIK 0001720772 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,018 F1 · security: The shares of Common Stock were automatically exercised and sold under a pre-planned 10b5-1 trading plan. F2 · price: On January 16, 2020, the Reporting Person sold an aggregate of 42,018 shares of the Issuer's Common Stock at a weighted average price of $5.98 per share. The highest sale price for the Common Stock was $6.00 per share and the lowest sale price was $5.89 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 16:06 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionStock Options (right to buy) · Derivative | 35,703 | $3.73 Strike: $3.73 | $133,172.19 |
DisclosureSEC source: 0001103021-20-000010 · wf-form4_157929516784215.xml · derivative · entry 5 Coelho Mary Theresa · CIK 0001720772 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,406 Underlying: Common Stock · 35,703 shares Expires 2029-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The shares of Common Stock were automatically exercised and sold under a pre-planned 10b5-1 trading plan. F4 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the exercise of stock options granted to the Reporting Person on January 17, 2019 under the Issuer's 2011 Equity Incentive Plan, as amended. The remainder of the stock options under this grant vest in equal portions on: (i) January 15, 2021; and (ii) January 15, 2022. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 16:06 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 18,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001103021-20-000010 · wf-form4_157929516784215.xml · derivative · entry 4 Coelho Mary Theresa · CIK 0001720772 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,667 Underlying: Common Stock · 18,333 shares Expires 2022-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 18,333 Restricted Stock Units ("RSUs") granted to the Reporting Person on January 17, 2019 under the Issuer's 2011 Equity Incentive Plan, as amended. The remainder of the RSUs under this grant vest in equal portions on: (i) January 15, 2021; and (ii) January 15, 2022. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 16:06 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 35,703 | $3.73 | $133,172.19 |
DisclosureSEC source: 0001103021-20-000010 · wf-form4_157929516784215.xml · nonDerivative · entry 2 Coelho Mary Theresa · CIK 0001720772 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The shares of Common Stock were automatically exercised and sold under a pre-planned 10b5-1 trading plan. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 16:06 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 18,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001103021-20-000010 · wf-form4_157929516784215.xml · nonDerivative · entry 1 Coelho Mary Theresa · CIK 0001720772 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The shares of Common Stock were automatically exercised and sold under a pre-planned 10b5-1 trading plan. Read SEC document |
| January 17, 2019 Filed Jan 18, 2019 18:05 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantStock Options (right to buy) · Derivative | 107,109 | $0.00 Strike: $3.73 | $0.00 |
DisclosureSEC source: 0000899243-19-001537 · doc4.xml · derivative · entry 2 Coelho Mary Theresa · CIK 0001720772 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,109 Underlying: Common Stock · 107,109 shares Expires 2029-01-17 F3 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is the volume-weighted average price of the Company's common stock for the 30-day period ending on January 16, 2019. F4 · kind: The stock options were issued to the Reporting Person on January 17, 2019, pursuant to a grant under the Plan. The award is subject to time-based vesting and will vest in equal portions on: (i) January 15, 2020; (ii) January 15, 2021; and (iii) January 15, 2022. F4 · derivative.exercise_date: The stock options were issued to the Reporting Person on January 17, 2019, pursuant to a grant under the Plan. The award is subject to time-based vesting and will vest in equal portions on: (i) January 15, 2020; (ii) January 15, 2021; and (iii) January 15, 2022. Read SEC document |
| January 17, 2019 Filed Jan 18, 2019 18:05 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantRestricted Stock Units · Derivative | 55,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-001537 · doc4.xml · derivative · entry 1 Coelho Mary Theresa · CIK 0001720772 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2022-01-17 F1 · kind: The Restricted Stock Units ("RSUs") were issued to the Reporting Person on January 17, 2019, pursuant to a grant under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). The award is subject to time-based vesting and will vest in equal portions on: (i) January 15, 2020; (ii) January 15, 2021; and (iii) January 15, 2022. F2 · derivative.exercise_date: Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock. The Reporting Person has been granted the right to elect to defer actual payment of a vested RSU award, subject to compliance with Internal Revenue Code Section 409A. Read SEC document |
| October 29, 2018 Filed Oct 30, 2018 14:00 UTC | BALCHEM CORP BCPC · Entity 3839 | Tax withholdingCommon Stock | 1,187 | $96.42 | $114,450.54 |
DisclosureSEC source: 0001140361-18-041597 · form4.xml · nonDerivative · entry 1 Coelho Mary Theresa · CIK 0001720772 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,105 F1 · shares: The Company granted 5,605 restricted shares under the Company's Long-Term Incentive Program. The shares were subject to certain restrictions under the applicable Restricted Stock Grant Agreements. 1,187 of the 3,210 shares that vested October 26, 2018 were withheld to cover withholding taxes due upon vesting. F2 · balance_after: In connection with a Separation Agreement and General Release (SA&GR) between the Company and the reporting person, 1,050 shares previously reported as beneficially owned in connection with Restricted Stock Grant Agreements were forfeited. Read SEC document |
| October 26, 2018 Filed Oct 30, 2018 14:00 UTC | BALCHEM CORP BCPC · Entity 3839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,132 | $0.00 Strike: $74.57 | $0.00 |
DisclosureSEC source: 0001140361-18-041597 · form4.xml · derivative · entry 2 Coelho Mary Theresa · CIK 0001720772 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,337 Underlying: Common Stock · 1,132 shares Expires 2028-02-15 F3 · shares: On February 15, 2018, the reporting person was granted an option to purchase 5,030 shares of common stock scheduled to vest in installments of 20%, 40%, and 40% per year over the three-year period. The option reported herein as acquired resulted from the acceleration of vesting of 22.5% of such option in connection with a SA&GR. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 22:54 UTC | BALCHEM CORP BCPC · Entity 3839 | GrantStock Option · Derivative | 5,030 | $0.00 Strike: $74.57 | $0.00 |
DisclosureSEC source: 0001140361-18-009151 · form4.xml · derivative · entry 2 Coelho Mary Theresa · CIK 0001720772 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,030 Underlying: Common Stock · 5,030 shares Expires 2028-02-15 F2 · derivative.exercise_date: Options vest 20% year 1; 40% year 2; and 40% year 3. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 22:54 UTC | BALCHEM CORP BCPC · Entity 3839 | GrantCommon Stock | 1,260 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-009151 · form4.xml · nonDerivative · entry 1 Coelho Mary Theresa · CIK 0001720772 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,294 F1 · shares: Ownership of the restricted stock does not vest in Reporting person until four years from the grant date and is further subject to restrictions on transfer in accordance with the provisions of a Restricted Stock Grant Agreement between the Issuer and the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.